10:36 AM EST - Oncolytics Biotech Inc. : Announced a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. The phase 2 trial, known as IRENE, will investigate the use of pelareorep in combination with Incyte's anti-PD-1 checkpoint inhibitor retifanlimab (INCMGA00012) in patients with unresectable locally advanced or metastatic TNBC. Oncolytics Biotech Inc.
shares T.ONC are trading up $0.02 at $2.80.
